Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Some users on the PlayStation subreddit said they could connect to servers once again as of Saturday afternoon, while others said their service was still down or unreliable. Fortnite’s X account ...

Jeffrey Leiden is leaving Vertex Pharma after seven years as president and CEO, to be replaced by chief medical officer Reshma Kewalramani. Leiden isn’t heading off into the sunset, however.

Many fans and insiders thought that Denis Shapovalov's career had now entered a downward parabola from which he would never recover. The Canadian ace was considered as one of the best candidates ...